US20100221339A1 - Use of a combination of morphine and at least one opiate antagonist to treat opiate dependency and prevent non-oral opiate abuse among opiate addicts - Google Patents

Use of a combination of morphine and at least one opiate antagonist to treat opiate dependency and prevent non-oral opiate abuse among opiate addicts Download PDF

Info

Publication number
US20100221339A1
US20100221339A1 US12/161,397 US16139707A US2010221339A1 US 20100221339 A1 US20100221339 A1 US 20100221339A1 US 16139707 A US16139707 A US 16139707A US 2010221339 A1 US2010221339 A1 US 2010221339A1
Authority
US
United States
Prior art keywords
morphine
opiate
retarded
combination
naloxone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/161,397
Other languages
English (en)
Inventor
Lars von Hermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Pharma LP
Original Assignee
PHOENUX AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36675685&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20100221339(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by PHOENUX AG filed Critical PHOENUX AG
Assigned to PHOENUX AG reassignment PHOENUX AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HERMANN, LARS
Publication of US20100221339A1 publication Critical patent/US20100221339A1/en
Assigned to PURDUE PHARMACEUTICAL PRODUCTS L.P. reassignment PURDUE PHARMACEUTICAL PRODUCTS L.P. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PHOENUX AG
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US12/161,397 2006-01-19 2007-01-19 Use of a combination of morphine and at least one opiate antagonist to treat opiate dependency and prevent non-oral opiate abuse among opiate addicts Abandoned US20100221339A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06100578.1 2006-01-19
EP06100578A EP1810678A1 (de) 2006-01-19 2006-01-19 Verwendung einer Kombination von Morphin und Naloxon zur Drogensubstitution
PCT/EP2007/050540 WO2007082935A1 (de) 2006-01-19 2007-01-19 Verwendung einer kombination von morphin und mindestens einem opiatantagonisten zur behandlung von opiatabhängigkeit und zur verhinderung des nicht-oralen opiatmissbrauchs bei opiatsüchtigen

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/050540 A-371-Of-International WO2007082935A1 (de) 2006-01-19 2007-01-19 Verwendung einer kombination von morphin und mindestens einem opiatantagonisten zur behandlung von opiatabhängigkeit und zur verhinderung des nicht-oralen opiatmissbrauchs bei opiatsüchtigen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/187,374 Continuation US10507205B2 (en) 2006-01-19 2016-06-20 Methods of treating opiate dependency and preventing non-oral opiate abuse among opiate addicts

Publications (1)

Publication Number Publication Date
US20100221339A1 true US20100221339A1 (en) 2010-09-02

Family

ID=36675685

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/161,397 Abandoned US20100221339A1 (en) 2006-01-19 2007-01-19 Use of a combination of morphine and at least one opiate antagonist to treat opiate dependency and prevent non-oral opiate abuse among opiate addicts
US15/187,374 Active US10507205B2 (en) 2006-01-19 2016-06-20 Methods of treating opiate dependency and preventing non-oral opiate abuse among opiate addicts

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/187,374 Active US10507205B2 (en) 2006-01-19 2016-06-20 Methods of treating opiate dependency and preventing non-oral opiate abuse among opiate addicts

Country Status (19)

Country Link
US (2) US20100221339A1 (pt)
EP (2) EP1810678A1 (pt)
CN (2) CN101370503A (pt)
AT (1) ATE465735T1 (pt)
AU (1) AU2007206914B2 (pt)
CA (1) CA2637458C (pt)
CY (1) CY1110152T1 (pt)
DE (1) DE502007003589D1 (pt)
DK (1) DK1976524T4 (pt)
EA (1) EA014539B1 (pt)
ES (1) ES2345286T5 (pt)
HK (1) HK1198744A1 (pt)
HR (1) HRP20100373T4 (pt)
PL (1) PL1976524T5 (pt)
PT (1) PT1976524E (pt)
RS (1) RS51388B2 (pt)
SI (1) SI1976524T1 (pt)
UA (1) UA92380C2 (pt)
WO (1) WO2007082935A1 (pt)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9192570B2 (en) 2013-12-20 2015-11-24 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
WO2016193456A3 (en) * 2015-06-03 2017-01-12 Develco Pharma Schweiz Ag Opioid receptor antagonist for use in treating patients with severe constipation
WO2016193454A3 (en) * 2015-06-03 2017-01-12 Develco Pharma Schweiz Ag Dosage of naloxone

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007024428A1 (de) 2007-05-25 2008-11-27 Hermann, Holger Lars, Dr. med. Verwendung von Naloxon als Abususschutz bei Nicht-Opioiden und Nicht-Opiaten
EP2421515A2 (de) 2009-04-22 2012-02-29 Lars Holger Hermann Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid- antagonisten
JP2012087101A (ja) 2010-10-21 2012-05-10 Holger Hermann Lars オピオイドおよびオピオイド拮抗薬を含む微粒子医薬組成物
CN103695497B (zh) * 2013-12-20 2014-09-17 奇方(天津)医药科技有限公司 纳洛酮的酶法制备及其药物组合物
WO2015089530A1 (de) 2013-12-20 2015-06-25 G.L. PHARMA GmbH Orale darreichungsform mit verzögerter freisetzung enthaltend morphin und naloxon

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769372A (en) * 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US6228863B1 (en) * 1997-12-22 2001-05-08 Euro-Celtique S.A. Method of preventing abuse of opioid dosage forms
US20040110781A1 (en) * 2002-12-05 2004-06-10 Harmon Troy M. Pharmaceutical compositions containing indistinguishable drug components
US20040131552A1 (en) * 2002-09-20 2004-07-08 Alpharma, Inc. Sequestering subunit and related compositions and methods
US20050181046A1 (en) * 2000-02-08 2005-08-18 Benjamin Oshlack Tamper-resistant oral opioid agonist formulations
US20050191244A1 (en) * 2002-10-25 2005-09-01 Gruenenthal Gmbh Abuse-resistant pharmaceutical dosage form
US20070264326A1 (en) * 2005-05-24 2007-11-15 Flamel Technologies Anti-misuse oral microparticle medicinal formulation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1390772A (en) * 1971-05-07 1975-04-16 Endo Lab Oral narcotic composition
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5580876A (en) † 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
SE9301057L (sv) 1993-03-30 1994-10-01 Pharmacia Ab Beredning med kontrollerad frisättning
DE4325465B4 (de) * 1993-07-29 2004-03-04 Zenz, Michael, Prof. Dr.med. Orales pharmazeutisches Präparat für die Schmerztherapie
AT403988B (de) 1994-05-18 1998-07-27 Lannacher Heilmittel Festes orales retardpräparat
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
AU2059297A (en) * 1996-03-12 1997-10-01 Alza Corporation Composition and dosage form comprising opioid antagonist
DE59812355D1 (de) 1997-11-06 2005-01-13 Lannacher Heilmittel Orale Retard-Präparation enthaltend Tramadol sowie Verfahren zu ihrer Herstellung
PL193273B1 (pl) * 1997-12-22 2007-01-31 Euro Celtique Sa Postać dawkowania doustnego
AU2406299A (en) 1998-02-12 1999-08-30 Centrapharm Inc. Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect
DE60238756D1 (de) † 2001-05-11 2011-02-10 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
US20030044458A1 (en) † 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
CA2478523A1 (en) 2002-04-05 2003-10-16 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
AT503858B1 (de) 2003-06-05 2008-08-15 Lannacher Heilmittel Verfahren zur herstellung einer festen oralen pharmazeutischen zusammensetzung, enthaltend ein jodsalz
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
AU2006208627B8 (en) 2005-01-28 2009-08-13 Mundipharma Pty Limited Alcohol resistant dosage forms
GB2438401A (en) 2006-05-25 2007-11-28 Alpharma Aps Preparation of morphinan derivatives comprising N-demethylation, reductive amination and O-demethylation steps
HUE032156T2 (en) 2006-06-19 2017-09-28 Alpharma Pharmaceuticals Llc Pharmaceutical preparations

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769372A (en) * 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US6228863B1 (en) * 1997-12-22 2001-05-08 Euro-Celtique S.A. Method of preventing abuse of opioid dosage forms
US20050181046A1 (en) * 2000-02-08 2005-08-18 Benjamin Oshlack Tamper-resistant oral opioid agonist formulations
US20040131552A1 (en) * 2002-09-20 2004-07-08 Alpharma, Inc. Sequestering subunit and related compositions and methods
US20050191244A1 (en) * 2002-10-25 2005-09-01 Gruenenthal Gmbh Abuse-resistant pharmaceutical dosage form
US20040110781A1 (en) * 2002-12-05 2004-06-10 Harmon Troy M. Pharmaceutical compositions containing indistinguishable drug components
US20070264326A1 (en) * 2005-05-24 2007-11-15 Flamel Technologies Anti-misuse oral microparticle medicinal formulation

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9192570B2 (en) 2013-12-20 2015-11-24 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US9289425B2 (en) 2013-12-20 2016-03-22 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
WO2016193456A3 (en) * 2015-06-03 2017-01-12 Develco Pharma Schweiz Ag Opioid receptor antagonist for use in treating patients with severe constipation
WO2016193454A3 (en) * 2015-06-03 2017-01-12 Develco Pharma Schweiz Ag Dosage of naloxone

Also Published As

Publication number Publication date
US10507205B2 (en) 2019-12-17
CA2637458A1 (en) 2007-07-26
EA014539B1 (ru) 2010-12-30
DK1976524T4 (en) 2016-12-05
PT1976524E (pt) 2010-07-05
AU2007206914B2 (en) 2012-08-23
CN103893179A (zh) 2014-07-02
UA92380C2 (ru) 2010-10-25
DK1976524T3 (da) 2010-08-09
ATE465735T1 (de) 2010-05-15
EA200870182A1 (ru) 2009-02-27
AU2007206914A1 (en) 2007-07-26
EP1976524A1 (de) 2008-10-08
PL1976524T3 (pl) 2010-10-29
HRP20100373T4 (hr) 2016-12-16
CY1110152T1 (el) 2015-01-14
DE502007003589D1 (de) 2010-06-10
HRP20100373T1 (en) 2010-08-31
SI1976524T1 (sl) 2010-08-31
RS51388B2 (sr) 2018-02-28
WO2007082935A1 (de) 2007-07-26
ES2345286T3 (es) 2010-09-20
HK1198744A1 (en) 2015-06-05
EP1810678A1 (de) 2007-07-25
EP1976524B2 (de) 2016-08-10
PL1976524T5 (pl) 2017-12-29
CN101370503A (zh) 2009-02-18
RS51388B (en) 2011-02-28
EP1976524B1 (de) 2010-04-28
US20170136005A1 (en) 2017-05-18
ES2345286T5 (es) 2017-04-25
CA2637458C (en) 2015-03-10

Similar Documents

Publication Publication Date Title
US10507205B2 (en) Methods of treating opiate dependency and preventing non-oral opiate abuse among opiate addicts
KR100417490B1 (ko) 오피오이드 제형의 남용을 방지하는 방법
JP5566102B2 (ja) 医薬組成物
JP6258214B2 (ja) 注射による誤用に対処可能な錠剤
UA79069C2 (en) Peroral composition preventing from abuse of opioid agonists contained therein
MXPA04001210A (es) Formulaciones de agonista opioide con antagonista liberable y aislado.
KR20160031038A (ko) 오피오이드 효능제 및 격리된 길항제를 포함하는 제약 조성물
EP2618820A2 (en) Controlled release formulations of opioids
US20190231698A1 (en) Non-extractable Oral Solid Dosage Forms
WO2013153451A2 (en) Controlled release formulations of opioids

Legal Events

Date Code Title Description
AS Assignment

Owner name: PHOENUX AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HERMANN, LARS;REEL/FRAME:021355/0518

Effective date: 20080717

AS Assignment

Owner name: PURDUE PHARMACEUTICAL PRODUCTS L.P., CONNECTICUT

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PHOENUX AG;REEL/FRAME:034222/0761

Effective date: 20131217

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION